Pasireotide Therapy in Patients With Nelson's Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
Nelson Syndrome
Interventions
DRUG

Pasireotide

4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered

Trial Locations (4)

Unknown

Barts and the London NHS Trust, London

The Christie Hospital NHS Foundation Trust, Manchester

Oxford University Hospitals NHS Trust, Oxford

S10 2JF

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

The Christie NHS Foundation Trust

OTHER

collaborator

Oxford University Hospitals NHS Trust

OTHER

collaborator

Barts & The London NHS Trust

OTHER

lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

NCT01617733 - Pasireotide Therapy in Patients With Nelson's Syndrome | Biotech Hunter | Biotech Hunter